Top Suppliers:I want be here
Related CAS#:
71125-38-7 244241-47-2
942047-63-4 1309936-00-2
881399-30-0 244241-52-9
130262-92-9 130262-93-0
1794737-37-3 1262333-25-4

71125-38-7

71125-38-7 structure
71125-38-7 structure
  • Name: Meloxicam
  • Chemical Name: meloxicam
  • CAS Number: 71125-38-7
  • Molecular Formula: C14H13N3O4S2
  • Molecular Weight: 351.401
  • Catalog: API Antipyretic analgesics Non-steroidal anti-inflammatory drugs
  • Create Date: 2018-05-26 08:00:00
  • Modify Date: 2024-01-01 21:21:18
  • Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively.
Name meloxicam
Synonyms Meloxicam
Metacam
Parocin
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboximidic acid 1,1-dioxide
Meloxciam
4-hydroxy-2-méthyl-N-(5-méthyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxyde
2H-1,2-Benzothiazine-3-carboximidic acid, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide
Movatec
structure was taken from Chemical Abstracts Index Guide, number
4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
meloxicam (tautomer)
MOBIC
Mobicox
MFCD11046047
Movalis
MOBEC
Description Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively.
Related Catalog
Target

COX-2:0.49 μM (IC50)

COX-1:36.6 μM (IC50)
In Vitro Meloxicam (Compound 5) is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively[1]. Meloxicam inhibits COX+ tumor cells, but shows no cytotoxicity on CF41.Mg or MDCK cells at 0.25-25 µg/mL. Furthermore, Meloxicam in combination with doxorubicin, has no synergistic effect on CF41.Mg cells. Meloxicam (0.25 µg/mL) decreases CF41.Mg cell migration and invasion, induces decrease in MMP-2 expression, and increases β-catenin phophorylation in CF41.Mg cells, but does not affect the CF41.Mg cell apoptosis[2].
In Vivo Meloxicam (10 mg/kg) alone or in combination with rutin significantly decreases paw liking time on 1st day by 55% and 49% compared with the formalin-treated group, respectively, however the combination reduces time non-significantly on 3rd day in mice. Meloxicam alone or in combination with rutin also decreases relative liver weights, reduces MDA contents, induces liver SOD activities, hampers IL-1β content, and significantly reduces the number of positive caspase-3 immunoreactive cells in mice[3].
Cell Assay CF41.Mg and MDCK cells are seeded at a density of 1.5 × 103 cells/well into 96-well plates, cultured for 24 h and then exposed to 0-25 µg/mL Meloxicam alone or in combination with doxorubicin. To evaluate synergism and sensitization, doxorubicin is added at the same time and after 24 h, respectively. MDCK cells are exposed only to Meloxicam as a non-tumor negative control. Control groups are cultured without Meloxicam and doxorubicin, but the corresponding amount of DMSO is added to the medium. Following an incubation period of 24 and 48 h, cell growth is measured using the MTS assay, with the absorbance at 490 nm determined using a microplate reader. Each experiment is performed 3 times in triplicate[2].
Animal Admin Mice[3] Thirty-two mice are randomLy allocated into four groups, eight mice each. Groups are received 20 μL of 2.5% formalin injected in the plantar region of the right hind paw of mice on the 1st and 3rd days 1 h after administration of 1% DMSO (group 1; positive control group), 60 mg/kg rutin, orally (group 2), and oral treatment with 10 mg/kg Meloxicam (group 3), as well as combined treatment of rutin and Meloxicam (group 4). In all groups, drugs are administered once a day for duration of 7 days. On day 7, mice are euthanized and right hind paws plus livers are immediately excised, washed with ice-cold saline, blotted dry, and weighed. They are stored at −80°C till the time of analysis. Then the used animals will be frozen till being incinerated[3].
References

[1]. Lazer ES, et al. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J Med Chem. 1997 Mar 14;40(6):980-9.

[2]. Iturriaga MP, et al. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206.

[3]. Fikry EM, et al. Rutin and meloxicam attenuate paw inflammation in mice: Affecting sorbitol dehydrogenase activity. J Biochem Mol Toxicol. 2018 Feb;32(2).
Density 1.6±0.1 g/cm3
Boiling Point 581.3±60.0 °C at 760 mmHg
Melting Point 255ºC
Molecular Formula C14H13N3O4S2
Molecular Weight 351.401
Flash Point 305.4±32.9 °C
Exact Mass 351.034760
PSA 136.22000
LogP 3.35
Vapour Pressure 0.0±1.7 mmHg at 25°C
Index of Refraction 1.735
Water Solubility DMSO: soluble
Symbol GHS06
GHS06
Signal Word Danger
Hazard Statements H301
Precautionary Statements P301 + P310
Hazard Codes Xn: Harmful;
Risk Phrases R22
Safety Phrases 26
RIDADR UN 2811 6.1/PG 3
WGK Germany 3
RTECS DL0702000
Packaging Group III
HS Code 2934999090
HS Code 2934999090
Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Chemsrc provides CAS#:71125-38-7 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 71125-38-7 | Chemsrc address: https://www.chemsrc.com/en/baike/1083007.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved